null

null

null

null

null

null

null

null

null

null

null

null

null

null

Minimal long-term debt; cash-funded clinical-stage biotech with equity financing; 20% rate rise has negligible direct debt-service impact but raises future capital costs materially.

Low current debt exposure; primary risk is higher discount rates compressing DCF-based valuation and increasing cost of future equity raises in a rate-sensitive biotech market.

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

1) US-based transgenic cattle herd concentration (single domestic site risk); 2) Upstream bovine genomics and IVF reagents sourced via limited specialist vendors with no ex-US redundancy.

Revenues are predominantly US government contracts (BARDA/DoD); minimal international revenue exposure means sovereign currency devaluation risk is near-zero currently.

Effectively US-only revenue base; Sioux Falls, SD operations hub; no material international commercial presence, eliminating FX devaluation exposure in top markets.

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High dependency: SAB's proprietary transchromosomic (Tc) bovine herd is a non-substitutable biological asset; no alternate supplier exists for this core production platform.

Clinical-stage biopharmaceutical; cloud termination would disrupt data management and informatics but would not halt core biological manufacturing or clinical operations.

Government contract R&D and grant-funded drug development; cloud dependency is secondary infrastructure, not core value-creation mechanism.

API coupling risk is low; company operates a proprietary biological platform, not a software API-dependent model; third-party software integrations are standard and replaceable.

Low Howey risk; revenue model is government contracts and milestone payments for drug development services, not investment contracts or profit-sharing schemes.

Very High

Low GDPR/CCPA exposure; primary data is preclinical/clinical trial data governed by FDA/ICH GCP frameworks; limited consumer personal data collection.

Negligible antitrust risk; niche early-stage biotech with no dominant market position; operates in a fragmented, competitive biopharma landscape.

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Nearly 100% transactional/milestone-based via BARDA and DoD contracts; no recurring subscription revenue; revenue is lumpy and contract-renewal dependent.

Government contract milestones and grants; future commercialization via product licensing or royalties upon regulatory approval of human polyclonal antibody therapeutics.

Pricing set by government contract negotiation (cost-plus or fixed-price milestone); limited independent pricing power; stress scenario of budget cuts could eliminate revenue.

Low independent pricing power; pricing dictated by government procurement rules; commercial pricing authority will only emerge post-approval in a competitive antibody market.

Gross margins likely 40–60% on contract revenue given high fixed biological manufacturing costs; commercial-stage margins could expand to 70%+ with scale.

No free-rider problem; proprietary Tc bovine platform is not replicable; government contracts are exclusive engagements with no substitute pathway for counterparties.

Revenue growth is largely headcount-sublinear at scale; herd expansion and manufacturing automation drive output, but clinical and regulatory staff scale linearly with pipeline breadth.

Marginal cost of growth is moderate; scaling requires cattle herd expansion (capital-intensive, multi-year lead time) but not proportional headcount doubling.

Not applicable; SAB Biotherapeutics is not a franchise business model.

At 10x scale, CAC remains low given government-contract focus; key constraint is regulatory approval and manufacturing capacity, not customer acquisition economics.

No meaningful network effect; biological platform value does not increase with additional users; competitive moat is IP and herd uniqueness, not network dynamics.

7.7% Return on Assets (Excellent)

Moderate-high recession resistance; BARDA/DoD pandemic preparedness funding is largely non-cyclical, though budget sequestration or political risk could disrupt contracts.

US federal government (BARDA, DoD JPEO CBRND); represents substantially all current revenue, creating extreme customer concentration risk.

Potential future commercial customers: hospitals, health systems, and specialty pharma partners for approved polyclonal antibody therapeutics; currently pre-revenue in this segment.

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

Capital is being deployed toward future-state infrastructure: herd expansion, manufacturing scale-up, and GMP facility investment; not legacy maintenance capex.

0001833214

SABS